26 Matching Annotations
  1. Last 7 days
  2. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov
    Pre-clinical Modeling of Navtemadlin Pharmacokinetics, Pharmacodynamics, and Efficacy in IDH-wildtype Glioblastoma
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    pmc.ncbi.nlm.nih.gov/articles/PMC12402800/
  3. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov
    First-in-Human clinical trial of a small molecule EBNA1 inhibitor, VK-2019, in patients with Epstein-Barr positive nasopharyngeal cancer, with pharmacokinetic and pharmacodynamic studies
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    pmc.ncbi.nlm.nih.gov/articles/PMC11915201/
  4. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov
    Development of a First-in-Class Click Chemistry–Based Cancer Therapeutic, from Preclinical Evaluation to a First-in-Human Dose Escalation Clinical Trial
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    pmc.ncbi.nlm.nih.gov/articles/PMC12402790/
  5. www.sciencedirect.com www.sciencedirect.com
    An HIV fusion-inhibitory lipopeptide provides robust post-exposure prophylaxis and prevents viral reservoir seeding in macaques
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    sciencedirect.com/science/article/pii/S2211124725009994
  6. Aug 2025
  7. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov
    Preclinical Evaluation of DB-1419, a Novel Bifunctional and Bispecific Anti–B7-H3 × PD-L1 Antibody–Drug Conjugate
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    pmc.ncbi.nlm.nih.gov/articles/PMC12351279/
  8. Jul 2025
  9. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov
    M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    pmc.ncbi.nlm.nih.gov/articles/PMC12214875/
  10. Jun 2025
  11. 52.53.155.43 52.53.155.43
    PDF-html.html
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    52.53.155.43/bbb28230632658450b2bbad03fe0ee90e846e4ab/PDF-html.html
  12. Apr 2025
  13. 52.53.155.43 52.53.155.43
    PDF-html.html
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    52.53.155.43/7ed245dda8abe220d9eb54c311ccf72fed7ec91f/PDF-html.html
  14. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov
    AZD8701, an Antisense Oligonucleotide Targeting FOXP3 mRNA, as Monotherapy and in Combination with Durvalumab: A Phase I Trial in Patients with Advanced Solid Tumors
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    pmc.ncbi.nlm.nih.gov/articles/PMC11995004/
  15. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov
    LNS8801: An Enantiomerically Pure Agonist of the G Protein–Coupled Estrogen Receptor Suitable for Clinical Development
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    pmc.ncbi.nlm.nih.gov/articles/PMC11969138/
  16. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov
    Novel Amanitin-Based Antibody–Drug Conjugates Targeting TROP2 for the Treatment of Pancreatic Cancer
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    pmc.ncbi.nlm.nih.gov/articles/PMC11962393/
  17. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov
    First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid Tumors
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    pmc.ncbi.nlm.nih.gov/articles/PMC11964176/
  18. Mar 2025
  19. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov
    Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial)
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    pmc.ncbi.nlm.nih.gov/articles/PMC11911801/
  20. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov
    Phase I Trial of TTI-101, a First-in-Class Oral Inhibitor of STAT3, in Patients with Advanced Solid Tumors
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    pmc.ncbi.nlm.nih.gov/articles/PMC11911802/
  21. Feb 2025
  22. 52.53.155.43 52.53.155.43
    PDF-html.html
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    52.53.155.43/deda98f214fb7101517678313113daec3955e700/PDF-html.html
  23. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov
    The development and evaluation of a tublysine-based antibody-drug conjugate with enhanced tumor therapeutic efficacy
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    pmc.ncbi.nlm.nih.gov/articles/PMC11847841/
  24. www.sciencedirect.com www.sciencedirect.com
    HMPL-306 in relapsed or refractory IDH1- and/or IDH2-mutated acute myeloid leukemia: A phase 1 study
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    sciencedirect.com/science/article/pii/S2666634025000029
  25. Jan 2025
  26. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov
    First-in-Human Study of 23ME-00610, an Antagonistic Antibody for Genetically Validated CD200R1 Immune Checkpoint, in Participants with Advanced Solid Malignancies
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    pmc.ncbi.nlm.nih.gov/articles/PMC11734590/
  27. 52.53.155.43 52.53.155.43
    {DF-html.html
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    52.53.155.43/3dc4e399d61c995b3fe9dc0524da3c3db5e796e0/{DF-html.html
  28. Dec 2024
  29. 52.53.155.43 52.53.155.43
    mct-24-0266-html.html
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    52.53.155.43/e3c3817ac819dde6c15544fa19222c2e3fb37801/mct-24-0266-html.html
  30. Oct 2024
  31. www.ncbi.nlm.nih.gov www.ncbi.nlm.nih.gov
    Subcutaneous and orally self-administered high-dose carprofen shows favorable pharmacokinetic and tolerability profiles in male and female C57BL/6J mice
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    ncbi.nlm.nih.gov/pmc/articles/PMC11457584/
  32. Sep 2024
  33. www.ncbi.nlm.nih.gov www.ncbi.nlm.nih.gov
    Systematic Evaluation of Tyrosine Kinase Inhibitors as OATP1B1 Substrates Using a Competitive Counterflow Screen
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    ncbi.nlm.nih.gov/pmc/articles/PMC11417675/
  34. www.ncbi.nlm.nih.gov www.ncbi.nlm.nih.gov
    Phase 1 study of simlukafusp alfa (FAP-IL2v) with or without atezolizumab in Japanese patients with advanced solid tumors
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    ncbi.nlm.nih.gov/pmc/articles/PMC11377867/
  35. Aug 2024
  36. www.ncbi.nlm.nih.gov www.ncbi.nlm.nih.gov
    A multicenter, phase 1, Adult Brain Tumor Consortium trial of oral terameprocol for patients with recurrent high-grade glioma (GATOR)
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    ncbi.nlm.nih.gov/pmc/articles/PMC11293336/
  37. May 2024
  38. www.ncbi.nlm.nih.gov www.ncbi.nlm.nih.gov
    Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-line Treatment of KRAS-mutant Metastatic Colorectal Cancer: A Phase 1b Clinical Study
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    ncbi.nlm.nih.gov/pmc/articles/PMC11094418/
  39. Apr 2024
  40. www.ncbi.nlm.nih.gov www.ncbi.nlm.nih.gov
    ADCT-602, a Novel PBD Dimer–containing Antibody–Drug Conjugate for Treating CD22-positive Hematologic Malignancies
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    ncbi.nlm.nih.gov/pmc/articles/PMC10985467/